Replies to post #228153 on Avid Bioservices Inc (CDMO)

[biopharm]

Dr. Rolf Brekken : Peregrine Pharmaceuticals KOL :

Welcome New IASLC Members for July (listed by country, then name):

Rolf Brekken
United States
Cancer Research/Basic Sciences

https://www.iaslc.org/membership/newsletters/july-2015-newsletter

-----------------------------------------------

[biopharm]

Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis

Amanda Kirane1, Kathleen F Ludwig2, Noah Sorrelle1, Gry Haaland3, Tone Sandal4, Renate Ranaweera3, Jason E Toombs5, Miao Wang1, Sean P Dineen1, David Micklem6, Michael T. Dellinger7, James B. Lorens8, and Rolf A Brekken9,*

-
Author Affiliations

1Surgery, University of Texas Southwestern Medical Center
2Pediatrics, University of Texas Southwestern Medical Center
3Biomedicine, University of Bergen
4Biology, BerGenBio AS
5Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern
6Research, BerGenBio AS
7Surgery, University of Texas Southwestern Medical School
8Department of Biomedicine, University of Bergen, Norway
9Surgery, Pharmacology, University of Texas Southwestern Medical Center

I've touched before on BergenBio but I find all this fascinating... and when did PPHM seem to have those back to back days of 30M shares was it? that just so happened in March of 2014 and this was about the time that ex-PPHM Longhen Zhou went from BerGenBio back over to NantBioscience (part of Nantworks..) but heck, what isn't part of Nantworks so many divisions over there.



David Micklem:
https://no.linkedin.com/in/dmicklem

James Lorens:
https://no.linkedin.com/in/james-lorens-9ab51431
https://www.researchgate.net/profile/James_Lorens

Tone Sandal
Tone Sandal serves as Vice President of Research Services at BerGenBio AS.
http://www.bloomberg.com/research/stocks/private/person.asp?personId=108457135&privcapId=107144331&previousCapId=107144331&previousTitle=BerGenBio%20AS
https://www.researchgate.net/profile/Tone_Sandal

Longhen Zhou:
Experience
Head, Preclinical Development
NantBioScience, division of NantWorks, LCC
March 2014 – Present (2 years)101 Theory Street, Irivne, CA 92617

Director, Cancer Biology
BerGenBio AS
November 2012 – February 2014 (1 year 4 months)Bergen Area, Norway
BerGenBio AS is a privately-held biotech company focused on developing first-in-class therapeutics for metastatic and drug resistant cancers by targeting the epithelial to mesenchymal transition (EMT) process in cancer cells.

Head, Principal Investigator, Preclinical Dept.
NantWorks, LLC
October 2010 – November 2012 (2 years 2 months)Costa Mesa
•Direct a research team in the discovery and development of novel personalized medicine in oncology with focus on in vivo pharmacology, PK, PD, PK/PD and toxicology studies.
•Identify and implement strategy to take molecules from early discovery efforts through
Development and IND submission.
•Serve as a project team representative as well as provide mentorship to junior scientists and research associates.
•Initiate and manage external scientific interaction, collaborations and CROs.
•Built up and manage all aspects of the state-of-the-art vivarium facility and chair animal care program.

Senior Research Scientist
Abraxis BioScience
May 2009 – October 2010 (1 year 6 months)
Preclinical Discovery & Development for both small molecules and antibody drug (ADC)

Research Scientist
Peregrine Pharmaceuticals
January 2008 – May 2009 (1 year 5 months)
Preclinical development for antibody drug

Postdoctoral Scholar
University of California, Irvine
2003 – 2008 (5 years)

Novel target-based therapy

Visiting Fellow
National Cancer Instittue, National Institutes of Health
October 2000 – December 2002 (2 years 3 months)

angiogenesis & metastasis, signal transduction
..
..
https://www.linkedin.com/in/longen-zhou-8291a26?authType=name&authToken=KyhE&trk=prof-sb-browse_map-name

----------------------

Richard Godfrey, Chief Executive Officer of BerGenBio, commented:

"This promising new preclinical data demonstrates the rationale for combining BGB324 with immune checkpoint inhibitors to treat aggressive cancer. In addition to the ongoing development of BGB324 in AML and NSCLC, this data suggests that BGB324 could also be used in combination with cancer immunotherapeutic agents to enhance their efficiency."

http://www.news-medical.net/news/20150921/BGB324-shows-enhanced-tumour-clearance-in-mouse-carcinoma-models.aspx

-----------------------------------------------

As an added bonus, how about former Dr. Brekken lab member Ms. Kristina, landing as scientist at BerGenBio. Travel and see the world Kristina : ) I'd like that one day....but must be patient for the PPHM breakout...